×

Amgen's cancer drug fails to improve survival rates

8:03 AM ET Thu, 14 Aug 2014

Yaron Werber, Citi Investment Research, shares his thoughts on news Kyprolis failed to meet its primary endpoint of improving overall survival for patients with multiple myeloma.